Progyny, Inc.

Stage 3 · Topping · week 7

As of Oct 22, 2026, Progyny is in Stage 3, the topping phase, now in week 7 (since Sep 9, 2026). It closed at $29.12, 10.0% below its 52-week high and above its 200-day average, which is rising.

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. More about the company

$29.12

+2.39% today

$2.2B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is PGNY early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 38w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 2w → S3 7w → S4 8w → S1 6w → S2 8w → S3 5w → S4 38w → S1 8w → S2 7w → S3 3w → S2 4w → S3 5w → S2 10w → S3 2w → S4 5w → S1 2w → S2 9w → S3 4w → S4 10w → S1 4w → S2 12w → S3 6w current

Total tracked: 165 weeks across 22 stage runs.

PGNY among Healthcare Plans3rd of 11 by relative strength

All 11 →

Stocks in Healthcare Plans ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CNCCentene Corporation	Stage 2 · wk 1	94	+14.8%
2	OSCROscar Health, Inc. Class A	Stage 2 · wk 22	87	+9.1%
3	PGNYProgyny, Inc.	Stage 3 · wk 7	86	+12.7%
4	CLOVClover Health Investments, Corp. Class A	Stage 2 · wk 2	85	+3.5%
5	HUMHumana Inc.	Stage 2 · wk 2	84	+12.3%
6	ELVElevance Health, Inc.	Stage 2 · wk 6	76	+11.7%
7	UNHUnitedHealth Group Incorporated	Stage 3 · wk 7	69	+14.5%
8	CVSCVS Health Corporation	Stage 3 · wk 7	68	+10.8%

vs 52W High

-10.0%

$16.30 lo$32.36 hi

10.0% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 7

1w13w26w

Week 7, distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

19.8%

200 DMA: $24.31 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.67x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↗ ⇈

Short-term trend rising gently, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+12.7%

-6.6%

+64.8%

YTD

+13.1%

+50.0%

Scan Membership

Breakout Watch

Latest: 2025-05-21

8 appearances in last 60 days. First seen: 2020-08-11.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 7 · Vol 0.67x

2026-10-21S3

Wk 7 · Vol 0.49x

2026-10-20S3

Wk 6 · Vol 1.10x

2026-10-19S3

Wk 6 · Vol 0.67x

2026-10-16S3

Wk 6 · Vol 0.77x

2026-10-15S3

Wk 6 · Vol 0.90x

2026-10-14S3

Wk 6 · Vol 0.66x

2026-10-13S3

Wk 5 · Vol 0.90x

2026-10-12S3

Wk 5 · Vol 0.70x

2026-10-09S3

Wk 5 · Vol 0.59x

2026-10-08S3

Wk 5 · Vol 1.46x

2026-10-07S3

Wk 5 · Vol 1.96x

Moving averages & range

50 DMA

$26.57

200 DMA

$24.31

52W High

$32.36

52W Low

$16.30

5D Low

$26.86

Resistance levels (recent highs)

20d High

$29.12

60d High

$31.53

120d High

$32.36

250d High

$32.36

Next resistance

+8.3%

to 60d High

P/E (TTM)

31.7

Forward 12.6

Earnings Growth (YoY)

+78.9%

Revenue +5.3%

ROE

+16.2%

Profit margin +6.0%

Dividend Yield

0.00%

P/B 4.9

Progyny: quick answers

What stage is Progyny in?

As of Oct 22, 2026, Progyny (PGNY) is in Stage 3, the topping phase. It entered Stage 3 on Sep 9, 2026 and is in week 7. What the four stages mean

Is Progyny in an uptrend?

Its uptrend has stalled. Progyny is in Stage 3, the topping phase that follows an advance. It trades 19.8% above its 200-day average, which is rising.

How far is Progyny from its 52-week high?

Progyny closed at $29.12 on Oct 22, 2026, 10.0% below its 52-week high of $32.36. Its 52-week low is $16.30.

How has Progyny performed over the past year?

As of Oct 22, 2026, Progyny is up 50.0% over the past year and up 13.1% so far in 2026.

Which sector and industry is Progyny in?

Progyny is in the Healthcare Plans industry, part of the Health Care sector.

About this companyHealth Care· Healthcare Plans

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.